Advertisement

Topics

Dose-Ranging Study of PSI-7977 in Combination With SOC in Treatment Naïve GT 1 HCV Patients

2014-07-23 21:11:01 | BioPortfolio

Summary

This Multi-center, Double-Blind, Parallel Group, Randomized, Placebo-Controlled, Dose Ranging Study will Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Oral Administration of PSI-7977 in Combination with Standard of Care (Pegylated Interferon and Ribavirin) in Treatment-Naïve Patients with Chronic HCV Infection Genotype 1. Approximately 60 treatment-naive GT-1 HCV infected patients will be enrolled in three parallel cohorts. Each cohort will receive PSI-7977, ranging from 100mg to 400mg, or matching placebo tablets, on Days 0-28. Patients will also receive treatment with SOC (PEG-IFN and RBV) starting on Day 0 of this trial, and continuing for 48 weeks. Eligible patients will be randomized to one of the 3 active cohorts based upon stratification for IL-28b status; each cohort will consist of twenty (20) subjects, with 16 subjects assigned to active PSI-7977 and 4 subjects assigned to matching placebo in a 4:1 randomization.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Conditions

Hepatitis C

Intervention

PSI-7977

Location

Quest Clinical Research
San Francisco
California
United States
94115

Status

Active, not recruiting

Source

Pharmasset

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:11:01-0400

Clinical Trials [1341 Associated Clinical Trials listed on BioPortfolio]

Efficacy Study of Combined Hepatitis A and Hepatitis B Vaccine to Protect Against Hepatitis B in Hemodialysis Patients

Does vaccinating hemodialysis patients with Twinrix® (combination vaccine against hepatitis A and hepatitis B) result in a difference in hepatitis B antibody response in comparison to the...

Investigation of Hepatitis B and Hepatitis C in Taiwan

The purpose of this study is to investigate the differences of genotypes of hepatitis B and hepatitis C in Taiwan.

Management of Hepatitis C in HIV-Infected and Uninfected IDUs

The purpose of this study is to determine if hepatitis C has damaged the liver, whether each subject's hepatitis C is treatable with currently available medicines, whether patient educatio...

Activation of Hepatitis B Virus (HBV) in Hepatitis B Surface Antigen (HBsAg) - Negative But Hepatitis B Core Antibody (Anti-HBc) - Positive Patients

Individuals with resolved hepatitis B, characterized as hepatitis B surface antigen (HBsAg)-negative and hepatitis B core antibody-positive, have latent hepatitis B virus (HBV) infection i...

A Safety and Efficacy Study of the Hepatitis E Vaccine in Nepal.

The purpose of this study is to determine if a hepatitis E vaccine is safe and able to prevent symptomatic liver disease due to the hepatitis E virus.

PubMed Articles [1191 Associated PubMed Articles listed on BioPortfolio]

Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain.

Hepatitis delta virus (HDV) is a defective agent that only replicates in the presence of the hepatitis B virus. Accordingly, HDV acquisition may occur as superinfection of HBsAg+ carriers or following...

Pretreatment Hepatitis B Viral Load Predicts Long-term Hepatitis B Response after Anti-hepatitis C Therapy in Hepatitis B/C Dual-infected Patients.

We aimed to investigate the long-term outcomes in hepatitis B (HBV)/hepatitis C (HCV) dual-infected patients after anti-HCV therapy.

Hepatitis E Virus Genotype 1 and Hepatitis A Virus Dual Infection in Pediatric Patients with a Low Socioeconomic Status from Mexico.

We aimed to detect and characterize hepatitis E virus (HEV) RNA in sera samples from a pediatric population infected with the hepatitis A virus (HAV) exhibiting acute hepatitis and to correlate the in...

Prevalence of non A to E hepatitis in Mumbai, India.

Acute viral hepatitis is a common problem in India. World wide data shows that 5 to 20 percent of this is caused by non A-E hepatitis. There is no data in India regarding non A-E hepatitis. We carried...

Clinical and laboratory characteristics of hepatitis d in Republic of Sakha (Yakutia).

Inrtroduction: The epidemiological situation for hepatitis D has changed significantly. Reduced population authors infection due to a sharp decline in hospitalizations from Central Asia regions, the C...

Medical and Biotech [MESH] Definitions

INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D).

A family of hepatotropic DNA viruses which contains double-stranded DNA genomes and causes hepatitis in humans and animals. There are two genera: AVIHEPADNAVIRUS and ORTHOHEPADNAVIRUS. Hepadnaviruses include HEPATITIS B VIRUS, duck hepatitis B virus (HEPATITIS B VIRUS, DUCK), heron hepatitis B virus, ground squirrel hepatitis virus, and woodchuck hepatitis B virus (HEPATITIS B VIRUS, WOODCHUCK).

A species in the genus HEPATOVIRUS containing one serotype and two strains: HUMAN HEPATITIS A VIRUS and Simian hepatitis A virus causing hepatitis in humans (HEPATITIS A) and primates, respectively.

INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.

INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.

More From BioPortfolio on "Dose-Ranging Study of PSI-7977 in Combination With SOC in Treatment Naïve GT 1 HCV Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...


Searches Linking to this Trial